Farnesyltransferase inhibitors.
Kurzrock
Razelle
R
The University of Texas M. D. Anderson Cancer Center, TX, USA.
D000215:Acylation / Q000187:drug effects; D000368:Aged; D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors*; D011905:Genes, ras; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D015363:Quinolones / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D018631:ras Proteins / Q000378:metabolism
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D015363:Quinolones; D051231:Farnesyltranstransferase; D018631:ras Proteins; C402769:tipifarnib